-
Mashup Score: 1
OncoInfluencers to Follow on Social Media: Dr. Komal Jhaveri / Breast Cancer, cancer, Komal Jhaveri, LinkedIn, Memorial Sloan Kettering Cancer Center,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 77Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer - 2 month(s) ago
npj Breast Cancer – Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ MBC. Work done with our amazing fellow @nickvmai and colleagues like Carlos dos Anjos @PedramRazaviMD @JoshDragoMD l @ChandarLab now published @MSK_DeptOfMed https://t.co/QHTnpsFbWE.
-
-
Mashup Score: 2Komal Jhaveri on LinkedIn: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy… - 4 month(s) ago
Phase 1a/1b trial of Imlunestrant, brain penetrant oral SERD as monotherapy or in combination with targeted therapies in HR+ HER2 – MBC now published in JCO…
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/fmQQOwd24e
-
-
Mashup Score: 62
PURPOSE To investigate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of inavolisib, a potent and selective small-molecule inhibitor of p110α that promotes the degradation of mutated p110α, in combination with palbociclib and endocrine therapy (ET), in a phase I/Ib study in patients with PIK3CA-mutated, hormone receptor–positive/human epidermal growth factor receptor 2–negative locally advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT03006172). METHODS Women ≥18 years of age received inavolisib, palbociclib, and letrozole (Inavo + Palbo + Letro arm) or fulvestrant (Inavo + Palbo + Fulv arm) until unacceptable toxicity or disease progression. The primary objective was to evaluate safety or tolerability. RESULTS Fifty-three patients were included, 33 in the Inavo + Palbo + Letro arm and 20 in the Inavo + Palbo + Fulv arm. Median duration of inavolisib treatment was 15.7 and 20.8 months (cutoff: March 27, 2023), respectively. Treatm
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Phase I/Ib trial-Inavolisib + Palbociclib + ET for PIK3CAm HR+ HER2- MBC now published .@OncoAlert @MSKCancerCenter @MSK_DeptOfMed @JCO_ASCO https://t.co/d0KueXutkw #bcsm
-
-
Mashup Score: 25New York medical school eliminates tuition after $1bn gift - 11 month(s) ago
The record-breaking donation came from a 93-year-old former professor, who is the widow of a wealthy investor.
Source: www.bbc.comCategories: General Medicine News, Hem/OncsTweet-
New York medical school eliminates tuition after $1bn gift - What a fantastic way to give back! #diversity #inclusion #affordable. Nicely done Dr Ruth Gottesman! https://t.co/RUoJiRoYGn
-
-
Mashup Score: 70FDA approves capivasertib with fulvestrant for breast cancer - 1 year(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
FDA approves capivasertib (AKTi) with fulvestrant for HR pos HER2- MBC for those whose tumors harbor PIK3CA/AKT1/PTEN alterations. Foundation one CDX assay was approved as the companion diagnostic. Another option for our patients! @OncoAlert https://t.co/0ZYCEhjVy0
-
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 1 year(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
FDA approves capivasertib (AKTi) with fulvestrant for HR pos HER2- MBC for those whose tumors harbor PIK3CA/AKT1/PTEN alterations. Foundation one CDX assay was approved as the companion diagnostic. Another option for our patients! @OncoAlert https://t.co/0ZYCEhjVy0
-
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 1 year(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
FDA approves capivasertib (AKTi) with fulvestrant for HR pos HER2- MBC for those whose tumors harbor PIK3CA/AKT1/PTEN alterations. Foundation one CDX assay was approved as the companion diagnostic. Another option for our patients! @OncoAlert https://t.co/0ZYCEhjVy0
-
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 1 year(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
FDA approves capivasertib (AKTi) with fulvestrant for HR pos HER2- MBC for those whose tumors harbor PIK3CA/AKT1/PTEN alterations. Foundation one CDX assay was approved as the companion diagnostic. Another option for our patients! @OncoAlert https://t.co/0ZYCEhjVy0
-
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 1 year(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
FDA approves capivasertib (AKTi) with fulvestrant for HR pos HER2- MBC for those whose tumors harbor PIK3CA/AKT1/PTEN alterations. Foundation one CDX assay was approved as the companion diagnostic. Another option for our patients! @OncoAlert https://t.co/0ZYCEhjVy0
-
RT @oncodaily: 📌OncoInfluencers to Follow on Social Media: Dr. Komal Jhaveri (@jhaveri_komal) https://t.co/yQOqfd4v7C #Cancer #OncoInflue…